Video
Investigative Treatment for Advanced Prostate Cancer Uses Targeted Approach
The investigative therapy targets a specific molecule that is generally only expressed on the prostate cancer cell, according to a recent interview.
New research presented at the American Society of Clinical Oncology 2021 annual meeting has found encouraging results with the use of 177Lu-PSMA-617 in patients with advanced prostate cancer.
Researcher Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, said any kind of cancer therapy should be as targeted as possible in order to attack cancer cells while avoiding healthy cells. Therapy with 177Lu-PSMA-617 is very precise, Morris said, because it targets a specific molecule that is generally only expressed on the prostate cancer cell.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
